Results 31 to 40 of about 691 (170)

In Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA: An Encouraging Milestone to Further Clinical Drug Development

Journal of Immunology Research, 2020
Anti-drug antibodies (ADAs), specific for biotherapeutic drugs, are associated with reduced serum drug levels and compromised therapeutic response. The impact of ADA on the bioavailability and clinical efficacy of blockbuster anti-hTNF-α monoclonal ...
Obinna C. Ubah, Andrew J. Porter, Caroline J. Barelle   +2 more
doaj   +2 more sources

Joint Modeling of Longitudinal Data and Potentially Informative Visiting Process to Dynamically Predict Future Visit Times. [PDF]

Stat Med
ABSTRACT Frequent visits in cohort studies are important as they enable, among others, the assessment of disease progression and treatment effectiveness. In HIV studies, extended intervals between visits have been shown to be associated with adverse outcomes (e.g., antiretroviral therapy interruption).
Stamoulopoulos A, Thomadakis C, Touloumi G.   +2 more
europepmc   +2 more sources

Screening and characterization of inhibitory vNAR targeting nanodisc-assembled influenza M2 proteins

iScience, 2023
Summary: Influenza A virus poses a constant challenge to human health. The highly conserved influenza matrix-2 (M2) protein is an attractive target for the development of a universal antibody-based drug.
Chuandi Yu, Wen Ding, Lei Zhu, Yuhang Zhou, Yingkui Dong, Ling Li, Juanjuan Liu, Yizhuo Wang, Zehua Li, Lina Zhu, FaJun Chen, Maosen Ruan, Dongming Qian, Yujuan Wang, Bo Wu, Huangtao Xu, Ming Li, Yunchen Bi, Hao Wang, Weiqian Wang, Peng Chao, Lei Xing, Bing Shen, Han Dai, Lisha Zha, Hongxin Zhao, Junfeng Wang   +26 more
doaj   +3 more sources

Unleashing the power of shark variable single domains (VNARs): broadly neutralizing tools for combating SARS-CoV-2 [PDF]

Frontiers in Immunology, 2023
The pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) generated a joint global effort to develop vaccines and other treatments that could mitigate the negative effects and the rapid spread of the virus.
Olivia Cabanillas-Bernal, Blanca J. Valdovinos-Navarro, Karla E. Cervantes-Luevano, Noemi Sanchez-Campos, Alexei F. Licea-Navarro   +4 more
doaj   +2 more sources

Unique antibodies across the animal kingdom (birds, camelids, and sharks): therapeutic potential against human respiratory viral infections [PDF]

Frontiers in Immunology
Antibodies represent indispensable tools in the armamentarium against infectious diseases, with widespread application in prophylactic, therapeutic, and diagnostic settings.
Ammar A. Basabrain, Ammar A. Basabrain, Thamir A. Alandijany, Thamir A. Alandijany   +3 more
doaj   +2 more sources

Preparation of pH-sensitive nanogels bioconjugated with shark antibodies (VNAR) for targeted drug delivery with potential applications in colon cancer therapies. [PDF]

PLoS ONE
Cancer is the second leading cause of death worldwide. To combat this disease, novel and specialized therapeutic systems are urgently needed. This is the first study to explore a system that combines shark variable domain (Fv) of new antigen receptor ...
Lizbeth A Manzanares-Guevara, Jahaziel Gasperin-Bulbarela, Olivia Cabanillas-Bernal, Monserrat Renteria-Maciel, Angel Licea-Claverie, Eugenio R Méndez, Alexei F Licea-Navarro   +6 more
doaj   +2 more sources

Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs [PDF]

Biomarker Research
CAR-T cells are genetically modified T lymphocytes that express chimeric antigen receptors (CAR) on their surfaces. These receptors enable T lymphocytes to recognize specific antigens on target cells, triggering a response that leads to targeted ...
Shasha Guo, Xiaozhi Xi
doaj   +2 more sources

Shark-derived single-domain antibodies for the detection of decapod iridescent virus 1

Aquaculture Reports, 2023
Decapod iridescent virus 1 (DIV1) has emerged as a novel threat to shrimp farming. The development of a rapid, convenient, and accurate method for diagnosing DIV1 is urgently needed, serving as a key factor in the reduction of the risk of viral outbreaks.
Jinlin Chen, Wei Wang, Qin Zheng, Yunying Cheng, Qian Zhang, Shenfei Jiang, Jianming Chen   +6 more
doaj   +1 more source

The screening and anti-Raji lymphoma effect of Chiloscyllium plagiosum anti-CD20 VNARs

Frontiers in Marine Science
IntroductionB-cell lymphoma, a malignant proliferative disease originating from lymphoid tissue, poses a grave threat to human health. CD20 has emerged as a promising target for lymphoma treatment.
Qingyu Ren, Yu Sheng, Yu Sheng, Ling Sun, Feijian Zheng, Chengwu Hu, Jianqing Chen, Zhengbing Lyu, Chen Yuan, Xiaofeng Jiang, Xiaofeng Jiang, Xiaofeng Jiang   +11 more
doaj   +2 more sources

vNARs as Neutralizing Intracellular Therapeutic Agents: Glioblastoma as a Target. [PDF]

Antibodies (Basel)
Glioblastoma is the most prevalent and fatal form of primary brain tumors. New targeted therapeutic strategies for this type of tumor are imperative given the dire prognosis for glioblastoma patients and the poor results of current multimodal therapy.
Manzanares-Guzmán A, Lugo-Fabres PH, Camacho-Villegas TA.   +2 more
europepmc   +4 more sources